---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-282630"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:09:10.033540+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Imara completes sale of tovinontrine and PDE9 assets to Cardurion for $34.75M upfront

## Summary
- Closed asset sale on Nov 10, 2022; received $34.75M upfront cash payment from Cardurion.
- Stockholders approved sale at special meeting on Nov 9: 18,366,825 for, 11,907 against, 47,876 abstain.
- Eligible for up to $10M proof-of-concept milestone and $50M regulatory/commercial milestones.
- Pro forma financial information to be filed within four business days of closing.

## SEC filing metadata
- accession: 0001193125-22-282630
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312522282630/0001193125-22-282630-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312522282630/d752591d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-282630
- JSON: https://secwatch.observer/filing/0001193125-22-282630.json
- Plain text: https://secwatch.observer/filing/0001193125-22-282630.txt

## Key facts
- M&A Transactions
  Enliven Therapeutics, Inc. completed a disposition involving Cardurion Pharmaceuticals, Inc. for $34,750,000 upfront cash payment (closed 2022-11-10).
  - Action: disposition
  - Counterparty: Cardurion Pharmaceuticals, Inc.
  - Consideration: $34,750,000 upfront cash payment
  - Closing: 2022-11-10
  source text: On November 10, 2022, the Asset Sale was consummated and, in accordance with the Asset Purchase Agreement, Cardurion paid to Imara an upfront cash payment of $34,750,000 upon closing of the Asset Sale.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312522282630/0001193125-22-282630-index.htm
- Shareholder Votes
  Enliven Therapeutics, Inc. shareholders approved Approval of the sale of assets related to the PDE9 program to Cardurion at the 2022-11-09 meeting.
  - Outcome: passed
  - Meeting: 2022-11-09
  source text: Proposal No. 1: To approve the sale by the Company to Cardurion of tovinontrine (IMR-687) and all other assets of the Company related to its PDE9 program, pursuant to the terms of the Asset Purchase Agreement, for an upfront cash payment of $34,750,000 upon closing of the Asset Sale (in addition to $250,000 previously paid by Cardurion to the Company upon execution of a non-binding term sheet), a $10,000,000 potential future payment that may become payable if Cardurion achieves a proof of concept milestone or other specified clinical milestones and a $50,000,000 potential future payment that may become payable if Cardurion achieves specified regulatory and/or commercial milestone events, in each case as described in the Asset Purchase Agreement and subject to the terms and conditions of the Asset Purchase Agreement (the “ Asset Sale Proposal ”). This proposal was approved by the requisite vote of the Company’s stockholders. For Against Abstain Broker Non-Votes 18,366,825 11,907 47,876
  evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312522282630/0001193125-22-282630-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.